These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 32708464)

  • 1. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
    Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.
    Das R
    Crit Rev Oncog; 2024; 29(1):69-81. PubMed ID: 38421715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
    Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
    Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
    Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
    Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.
    Escribà-Garcia L; Alvarez-Fernández C; Caballero AC; Schaub R; Sierra J; Briones J
    Oncoimmunology; 2019; 8(2):e1546543. PubMed ID: 30713807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
    Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
    J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
    Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM
    Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turned on by danger: activation of CD1d-restricted invariant natural killer T cells.
    Lawson V
    Immunology; 2012 Sep; 137(1):20-7. PubMed ID: 22734667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .
    Bassiri H; Das R; Guan P; Barrett DM; Brennan PJ; Banerjee PP; Wiener SJ; Orange JS; Brenner MB; Grupp SA; Nichols KE
    Cancer Immunol Res; 2014 Jan; 2(1):59-69. PubMed ID: 24563871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of decidual invariant natural killer T cells promotes lipopolysaccharide-induced preterm birth.
    Li L; Yang J; Jiang Y; Tu J; Schust DJ
    Mol Hum Reprod; 2015 Apr; 21(4):369-81. PubMed ID: 25589517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d-independent activation of invariant natural killer T cells by staphylococcal enterotoxin B through major histocompatibility complex class II/T cell receptor interaction results in acute lung injury.
    Rieder SA; Nagarkatti P; Nagarkatti M
    Infect Immun; 2011 Aug; 79(8):3141-8. PubMed ID: 21628519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct and overlapping effector functions of expanded human CD4+, CD8α+ and CD4-CD8α- invariant natural killer T cells.
    O'Reilly V; Zeng SG; Bricard G; Atzberger A; Hogan AE; Jackson J; Feighery C; Porcelli SA; Doherty DG
    PLoS One; 2011; 6(12):e28648. PubMed ID: 22174854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
    Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
    Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
    Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
    Front Immunol; 2020; 11():610010. PubMed ID: 33312179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
    Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
    ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.